Hydroxyurea-induced nail pigmentation in HIV patients

HIV Med. 1999 Oct;1(1):40-2. doi: 10.1046/j.1468-1293.1999.00001.x.

Abstract

Hydroxyurea (HU), a cytotoxic agent used in myeloproliferative disorders, has recently been introduced as an adjunct to combination anti-retroviral therapy. We describe abnormal nail pigmentation in four HIV-seropositive patients treated with HU and discuss the likely factors associated with its development.

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Black People
  • Drug Therapy, Combination
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1
  • Humans
  • Hydroxyurea / adverse effects*
  • Hydroxyurea / therapeutic use
  • Hyperpigmentation / chemically induced*
  • Male
  • Middle Aged
  • Nails / pathology*
  • Nucleic Acid Synthesis Inhibitors / adverse effects*
  • Nucleic Acid Synthesis Inhibitors / therapeutic use

Substances

  • Anti-HIV Agents
  • Nucleic Acid Synthesis Inhibitors
  • Hydroxyurea